OUR TEAM

LEADERSHIP

Cameron Durrant, MD, MBA

Cameron Durrant, MD, MBA

Chairman & CEO

​• Serial biotech experience as CEO, CFO, Chair, Exec Chair
• Merck, GSK, Pharmacia, J+J
• Launched 5 blockbusters during career, including antivirals

Dale Chappell, MD, MBA

Dale Chappell, MD, MBA

Chief Scientific Officer

• Founder, Black Horse Capital Advisors
• Decades of biotechnology investment experience
• HHMI Fellow, National Cancer Institute, Rosenberg Lab
• Multiple publications in T-cell therapy, GM-CSF and immunology pathways

Timothy Morris, CPA

Timothy Morris, CPA

Chief Operating and Financial Officer

• Over 36 years of professional finance and accounting experience
• Over 22 years as Chief Financial Officer with public biotechnology companies (IOVA, ACRX, VVUS, QCOR)
• Raised over $2 billion in equity and convertible securities for seven companies, completed four offerings for IOVA with over $1 billion in proceeds
• Oversaw increase in market cap of Iovance Biotherapeutics from $550 million to $4.2 billion (7x increase)
• Extensive deal experience with over 75 transactions and combined value in excess of $4 billion

Adrian Kilcoyne, MD, MBA

Adrian Kilcoyne, MD, MBA

Chief Medical Officer

• Leadership experience across Medical Affairs, Evidence Generation and R&D
• Over 15 years of clinical experience (AstraZeneca, Celgene, Sanofi, Roche, Baxter, Eli Lilly)
• Expertise in COVID-19 and CAR-T
• Directed numerous projects spanning oncology and lymphoma programs

Edward P. Jordan, MBA

Edward P. Jordan, MBA

Chief Commercial Officer

• Over 20 years experience building and leading commercial organizations
• Broad commercial experience spanning many therapeutic areas
• Biotech builder with biologic experience
• Extensive launch experience and builder of new therapeutic markets
• DBV Technologies, AMAG, TEVA, Schering-Plough

Bob Atwill, MBA

Bob Atwill, MBA

Head of Asia-Pacific Region

• Over 30 years of executive pharma, biotech, cell therapy and healthcare experience
• Corporate Officer in listed NYSE, NASDAQ, LSE, ASX and in other organisations for over 23-years
• Expertise in COVID-19, GvHD, virology, I/O and cell & gene therapy
• GSK, Sanofi-Synthélabo, Mesoblast and Benitec Biopharma
• APAC based cross-border M&A and capital service principal with Eaton Square

Omar Ahmed, PharmD

Omar Ahmed, PharmD

SVP, Clinical, Medical and Scientific Affairs

• 20-year pharmaceutical executive at Roche, Novartis, J&J
• Led multiple blockbuster launches setting a new SOC globally
• Led development of Janssen’s immunology portfolio strategy
• Deep expertise in I/O and biologics development
• Led collaborations with GSK, Merck, Astellas, Vertex, Idenix, and others ​

Morgan Lam

Morgan Lam

SVP, Development Operations & Project Management

• More than 23 years in clinical development and operations (Genentech, Geron, Balance Therapeutics, Schering-Plough)
• Over 15 years in program leadership roles for multiple early to mid-stage oncology and CNS assets
• 5+ years in senior leadership roles including being former COO (Humanigen) and President (Balance Therapeutics)
• Deep knowledge in drug development, program execution, organizational leadership and people management

 

BOARD OF DIRECTORS

Rainer Boehm, M.D., MBA

Rainer Boehm, M.D., MBA has served as a member of our Board since February 2018.  Dr. Boehm has been a biopharmaceutical industry leader for more than three decades. At Novartis for 29 years, he held roles of increasing responsibility culminating with his position as Chief Commercial and Medical Affairs Officer and as ad interim CEO of Novartis’ pharmaceuticals division. His background spans senior leadership, marketing, sales and medical affairs positions in both oncology and pharmaceuticals and he has led regions around the world, including North America, Asia and all emerging markets. Dr. Boehm has overseen the launch and commercialization of many new drugs in his career, including blockbuster breakthroughs Cosentyx and Entresto, and major oncology brands including Afinitor, Exjade, Tasigna, Femara, Zometa and Glivec. Dr. Boehm also currently serves on the board of directors for Cellectis, a clinical-stage biopharmaceutical company focused on immunotherapies based on gene-edited CAR-T cells; as an advisor in leadership development for senior executives at the GLG Institute in New York City; and as a consultant to healthcare companies. He graduated from the medical school at the University of Ulm in Germany and received his MBA from Schiller University at the Strasbourg campus in France. Dr. Boehm brings to the Board significant knowledge and experience within the biopharmaceutical industry, as well as financial acumen and operational experience.

Cameron Durrant, M.D., MBA

Cameron Durrant, M.D., MBA, has served as a member and Chairman of our Board since January 2016, and as our Chief Executive Officer since March 2016. From May 2014 to January 2016, Dr. Durrant served as Founder and Director of Taran Pharma Limited, a private semi-virtual specialty pharma company developing and registering treatments in Europe for orphan conditions. Dr. Durrant served as President and Chief Executive Officer of ECR Pharmaceuticals Co., Inc., a subsidiary of Hi-Tech Pharmacal Co., Inc., from September 2012 to April 2014. From January 2010 to September 2012, Dr. Durrant served as a consultant to several biopharma companies, as the Founder, CEO, CFO and director of PediatRx, Inc. and on the boards of several privately-held healthcare companies. He previously served as CEO of PediaMed Pharmaceuticals and has been a senior executive at Johnson and Johnson, Pharmacia, GSK and Merck.  Dr. Durrant served as a director of Immune Pharmaceuticals Inc. from July 2014 through August 2018 and serves on the board of directors of a privately held nano-biotech company and a medical device company.  Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia and his MBA from Henley Management College, Oxford, UK. Dr. Durrant brings to the Board extensive experience as a pharma/biotech entrepreneur, operating executive and board member, as well as his day to day operating experience as our Chief Executive Officer. 

Ronald Barliant, JD

Ronald Barliant, JD, has served as a member of our Board since January 2016. Mr. Barliant has been Of Counsel to Goldberg Kohn, Ltd. since January 2016, and immediately prior to that had served as a principal in Goldberg Kohn’s Bankruptcy & Creditors’ Rights Group since September 2002. He previously served as U.S. bankruptcy judge for the Northern District of Illinois from 1988 to 2002.  Mr. Barliant has represented debtors and creditors in complex bankruptcy cases, and counseled major financial institutions, business firms and boards of directors in connection with workouts.  He is a member of the board of directors of a closely held information technology company and the board of the estate representative supervising the liquidation of assets in the global crossing case.  Mr. Barliant brings to the Board valuable experience gained from a distinguished career as a counselor to numerous boards, considered judgment and experience with bankruptcy in the bankruptcy setting.

Cheryl Buxton, MA

Cheryl Buxton, MA, has, for the past 25 years, worked at Korn/Ferry International, the world’s largest executive search company.  She is the Korn/Ferry Vice Chairman, Global Sector Leader, Pharmaceuticals, based in the firm’s Princeton office. Ms. Buxton conducts senior level assignments, with a special focus on research driven organizations. She also leads the R&D sector for the Pharmaceutical and Consumer divisions within Korn/Ferry.  Ms. Buxton joined the Firm’s London office and European headquarters before spending time in Paris and then relocating to Princeton in 1997. Prior to joining Korn/Ferry, Ms. Buxton was human resources director for Johnson & Johnson Pharmaceuticals (Cilag Ltd), based in the U.K., where her focus was on organizational issues and strategic resourcing and guidance on European directives. She also provided human resources support to three smaller companies in the group for Europe. Her human resources career started at Bristol Myers Ltd., where she was responsible for its consumer and pharmaceutical business. Ms. Buxton holds a master’s degree in employment law and industrial relations from Leicester University, a degree in Nursing, a diploma in personnel management and is a member of the Institute of Personnel and Development.  Ms. Buxton is on the Executive Council for Springboard, a non-profit organization encouraging women entrepreneurs in Life Sciences, and the Advisory Board for South Asia Pharmaceutical Council.  She previously was on Board of SIFE. A keen horsewoman, she is a competitive amateur show jumper and endurance rider. Ms. Buxton brings to the Board significant knowledge and experience within the biopharmaceutical industry, as well as an extensive executive network.

Dale Chappell M.D., MBA

Dale Chappell, M.D., MBA, has served as a member of our Board as director of the Company since February 2021. Dr. Chappell joined Humanigen in July 2020 as full-time chief scientific officer after serving in an interim capacity for the Company. He began his career as a Howard Hughes Medical Institute fellow at the National Cancer Institute where he studied tumor immunology and published in the field of T-cell therapy, immunology pathways, and granulocyte-macrophage colony-stimulating factor (“GM-CSF”), an immune system protein that initiates the cytokine storm that can occur in COVID-19. Dr. Chappell is also the founder of Black Horse Capital with decades of biotechnology investment experience.